Stock Market & Financial Investment News

News Breaks February 9, 2010 08:03 EDT AMGN theflyonthewall.com: Amgen should be bought following denosumab results, says Oppenheimer After Amgen announced that its denosumab was superior to Novartis' (NVS) Zometa in a trial involving SRE prevention in prostate cancer patients with bone metastases, Oppenheimer thinks that the drug will almost certainly be approved by the FDA for SRE prevention in 2011. The firm recommends adding to Amgen positions following the results of the trial and it maintains an Outperform rating on the stock. :theflyonthewall.com News For AMGN From The Last 14 Days Check below for free stories on AMGN the last two weeks. There are 6 items on the Fly with pertinent information. Sign up for a free trial to see the rest of the stories you've been missing. May 16, 2012 18:11 EDT AMGN theflyonthewall.com: Amgen's Rilotumumab data identifies potential predictive biomarker Amgen announced results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab, or AMG 102. This analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with rilotumumab in combination with chemotherapy improved median overall survival in patients whose tumors exhibited high MET protein expression. :theflyonthewall.com 18:09 EDT AMGN theflyonthewall.com: Amgen's BiTE antibody Blinatumomab achieves high rate of complete response Subscribe for More Information :theflyonthewall.com May 9, 2012 08:44 EDT AMGN theflyonthewall.com: Amgen says has increased confidence in long-term outlook for Enbrel Subscribe for More Information :theflyonthewall.com 08:39 EDT AMGN theflyonthewall.com: Amgen says will continue to increase dividend "meaningfully" over time Says at end of Q1 had $3.6B in buyback authorization remaining, will continue to repurchase shares. :theflyonthewall.com 08:36 EDT AMGN theflyonthewall.com: Amgen says continues to see stabilization in Aranesp business by mid-year Says ESA business now represents "much smaller" proportion of overall sales. Says declines in ESA business more than offset by revenue gains in denosumab franchise in Q1. :theflyonthewall.com 08:33 EDT AMGN theflyonthewall.com: Amgen does not see ENBREL biosimilar competition for "foreseeable future" Subscribe for More Information :theflyonthewall.com